Nothing Special   »   [go: up one dir, main page]

MX2020008193A - Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a severa. - Google Patents

Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a severa.

Info

Publication number
MX2020008193A
MX2020008193A MX2020008193A MX2020008193A MX2020008193A MX 2020008193 A MX2020008193 A MX 2020008193A MX 2020008193 A MX2020008193 A MX 2020008193A MX 2020008193 A MX2020008193 A MX 2020008193A MX 2020008193 A MX2020008193 A MX 2020008193A
Authority
MX
Mexico
Prior art keywords
atopic dermatitis
treatment
nemolizumab
excoriation
moderate
Prior art date
Application number
MX2020008193A
Other languages
English (en)
Inventor
Ryosuke Mihara
Keiko Hirokawa
Nabil Kerrouche
Original Assignee
Nestle Skin Health Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Skin Health Sa filed Critical Nestle Skin Health Sa
Publication of MX2020008193A publication Critical patent/MX2020008193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente memoria se revelan métodos para el tratamiento selectivo de la dermatitis atópica (AD) en un sujeto que tiene excoriaciones de la piel, composiciones farmacéuticas para su uso en el tratamiento de la dermatitis atópica en un sujeto que tiene excoriaciones de la piel, usos de nemolizumab o un equivalente en la fabricación de un medicamento para el tratamiento de la dermatitis atópica en un sujeto que tiene excoriaciones de la piel, y métodos para la identificación de un sujeto que tiene dermatitis atópica que es probable que responda al tratamiento con nemolizumab o un equivalente del mismo.
MX2020008193A 2018-02-09 2019-02-08 Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a severa. MX2020008193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Publications (1)

Publication Number Publication Date
MX2020008193A true MX2020008193A (es) 2020-11-24

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008193A MX2020008193A (es) 2018-02-09 2019-02-08 Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a severa.

Country Status (14)

Country Link
US (1) US20200385476A1 (es)
EP (1) EP3749353A1 (es)
JP (2) JP2021512917A (es)
CN (1) CN112040976A (es)
AU (1) AU2019219608A1 (es)
BR (1) BR112020016144A2 (es)
CA (1) CA3090062A1 (es)
CL (1) CL2020002050A1 (es)
IL (1) IL276524A (es)
MX (1) MX2020008193A (es)
PH (1) PH12020551185A1 (es)
RU (1) RU2758378C1 (es)
SG (1) SG11202007558YA (es)
WO (1) WO2019155427A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
ES2339843T3 (es) 1999-06-02 2010-05-26 Chugai Seiyaku Kabushiki Kaisha Proteina receptora de hematopoyetina novedosa, nr10.
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
MY166429A (en) * 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US10544227B2 (en) * 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
SG11201803728YA (en) * 2015-11-30 2018-06-28 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions

Also Published As

Publication number Publication date
IL276524A (en) 2020-09-30
JP2023182632A (ja) 2023-12-26
BR112020016144A2 (pt) 2020-12-15
AU2019219608A1 (en) 2020-08-27
CA3090062A1 (en) 2019-08-15
TW201941800A (zh) 2019-11-01
CL2020002050A1 (es) 2020-12-11
JP2021512917A (ja) 2021-05-20
CN112040976A (zh) 2020-12-04
WO2019155427A1 (en) 2019-08-15
PH12020551185A1 (en) 2021-05-17
SG11202007558YA (en) 2020-09-29
RU2758378C1 (ru) 2021-10-28
US20200385476A1 (en) 2020-12-10
EP3749353A1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2017014020A (es) Terapia antimicrobiana.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
PH12017501300A1 (en) Novel iodophor composition and methods of use
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12019550265A1 (en) Composition comprising mannose oligosaccharide and process for making same and use thereof
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
SA519410324B1 (ar) صياغات رش إيبينيفرين
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.